Clinical trial

Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Stimulation on Smoking Consumption in Type 2 Diabetes Patients

Invitation only · Not applicable · 1 countries · Registry ID NCT06924697

Invitation onlyNot applicableInterventional

What this study is about

Diabetes has become an increasingly serious global health issue. In 2024, approximately 537 million adults were living with diabetes, and this number is projected to rise to 783 million by 2045, representing a 46% increase. Against the backdrop of a growing global diabetes epidemic, smoking among individuals with diabetes poses a significant threat, further exacerbating clinical and public health burdens. Despite over 50 years of tobacco control efforts, smoking remains one of the greatest public health threats in history, causing more than 8 million deaths annually worldwide. Among these, over 7 million deaths result from direct tobacco use, while approximately 1.3 million deaths are attributed to secondhand smoke exposure. Recent studies have shown that smoking increases the risk of developing prediabetes and diabetes. Moreover, individuals with diabetes who smoke have a higher risk of all-cause mortality, worsened chronic diabetic complications, an increased likelihood of developing cancer and cardiovascular diseases, and greater difficulty in glycemic control. Despite substantial evidence highlighting the detrimental effects of smoking on individuals with diabetes, national surveys from the 1990s indicated similar smoking prevalence rates between individuals with and without diabetes (27.3% and 25.9%, respectively). Although various smoking cessation methods are available, the success rate of quitting remains low, necessitating novel intervention strategies. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used in the treatment of type 2 diabetes. They exert hypoglycemic effects by stimulating insulin secretion in a glucose-dependent manner, inhibiting glucagon secretion, enhancing glucose uptake in muscle and adipose tissue, suppressing hepatic glucose production, delaying gastric emptying, and reducing appetite. Existing studies suggest that GLP-1 influences the brain's reward system, and GLP-1RAs have been shown to reduce nicotine dependence in animal models. Recent clinical research has demonstrated that GLP-1RAs can be used in combination with nicotine patches to facilitate smoking cessation. However, whether GLP-1RAs alone can directly promote smoking cessation in individuals with diabetes remains unclear. Therefore, this study aims to investigate the potential direct effects of GLP-1RAs on smoking cessation in patients with type 2 diabetes.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to 75 Years

SexMale

Healthy volunteersNot accepted

ConditionDiabetes Mellitus, Type 2, Nicotine Dependence, Cigarettes

Full registry criteria

Inclusion Criteria: 1. Male patients aged 18-75 years. 2. Diagnosis of type 2 diabetes mellitus (T2DM) based on the World Health Organization (WHO) criteria. 3. A history of smoking for at least one year. 4. Fagerström Test for Nicotine Dependence (FTND) score ≥4. 5. Eligible for treatment with glucagon-like peptide-1 receptor agonists (GLP1-RAs) or dipeptidyl peptidase-IV (DPP-IV) inhibitors but have not previously used these medications. 6. Patients who fully understand the study, voluntarily participate, and sign the informed consent form. Exclusion Criteria: 1. Diagnosis of type 1 diabetes or other specific types of diabetes. 2. Presence of diabetic ketoacidosis or severe diabetic complications. 3. Patients with severe cardiovascular, hepatic, renal, neurological, immune, or hematological diseases. 4. Presence of severe infections, malignancies, recent surgeries, or major trauma. 5. A history of severe recurrent hypoglycemia. 6. Severe gastrointestinal disorders, such as gastroparesis. 7. Poor adherence or inability to attend scheduled follow-up visits. 8. A history of pancreatitis or a high risk of developing pancreatitis. 9. Presence of severe psychiatric disorders, including schizophrenia, paranoid psychosis, bipolar disorder, or intellectual disability. 10. Contraindications to magnetic resonance imaging (MRI), such as metallic implants, pacemakers, or claustrophobia. \-

Treatments and study arms

Application of GLP-1RAs drugs

Drug

The pharmacological intervention will be given as an add-on to the standardised psychosocial T2DM treatment paradigm. Patients self-inject Semaglutide once a week or use other GLP-1RAs

DPP-4i group

Drug

The pharmacological intervention will be given as an add-on to the standardised psychosocial T2DM treatment paradigm. Patients took the DPP-4i according to their actual needs.

Primary outcomes

Fagerstrom Test of Nicotine Dependence (FTND) scoresFrom enrollment to the end of treatment at 24 weeks.At weeks 0 and 24

To evaluate smoking behavior and nicotine dependence before and after treatment, the Fagerström Test for Nicotine Dependence (FTND) will be administered at weeks 0, 1, 4, 12, and 24. Patient scores will be recorded.

Study locations

1 locations were listed when this page was built. The first 40 are shown.

Department of Endocrinology, East Hospital, Tongji University School of Medicine, 150 Jimo Road, Shanghai🇨🇳 Shanghai, Shanghai Municipality, China

Open map